Results 111 to 120 of about 120,528 (253)

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways [PDF]

, 2005
Prostate cancer is the second leading cause of cancer related deaths in men from the western world. Treatment of prostate cancer has relied on androgen deprivation therapy for the past 50 years.
J Edwards, Edwards, J., Bartlett, J.M.S., J. M. S. Bartlett   +3 more
core   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Study of prostatic pathology and its correlation with prostate specific antigen level

Journal of Pathology of Nepal, 2017
Background: Diseases primarily inflicting prostate gland are inflammation, benign prostatic hyperplasia and cancer. Prostate specific antigen is a protein produced by the cells of prostate gland. It has been widely used in the diagnosis and management of
S Hirachand, UMS Dangol, S Pradhanang, S Acharya   +3 more
doaj   +1 more source

An Implantable Scaffold Sequentially Releasing STING Agonist and B7‐H3 Antibody for Bone Metastasis Immunotherapy

Advanced Science, EarlyView.
We developed an implantable dual‐drug depot using GelMA for bone metastasis treatment, co‐delivering MSA‐2 and αB7‐H3‐loaded CaCO3 microparticles. Sustained release from GelMA scaffold enables MSA‐2 to activate STING signaling and enhance T‐cell infiltration and activation, while sequentially released αB7‐H3 blocks MSA‐2‐induced B7‐H3 upregulation ...
Qijun Lin, Hong Xiao, Shuai Fan, Kaimin Cai, Yanteng Xu, Xinwen Wang, Guanhong Chen, Chuandong Lang, Xinsheng Peng, Mingqiang Li, Yuhu Dai   +10 more
wiley   +1 more source

Association of Serum PSA, fPSA, and CEA Levels with Prognosis and Clinicopathological Characteristics in Prostate Cancer

Cancer Management and Research
Yeasin Ahamed,1,2 Lichao Wu,1 Shantanu Baral,1 Ashab Uddin Al-Raiyan,1 Weigui Sun1,2 1Department of Urology Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, 225001, People’s Republic of China; 2Clinical Medical College ...
Ahamed Y, Wu L, Baral S, Al-Raiyan AU, Sun W   +4 more
doaj  

Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti‐Tumor Immunity

Advanced Science, EarlyView.
Tumor‐associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME), with their metabolic states playing a critical role in tumor progression or regression. This review summarizes current understanding of TAM metabolic plasticity alongside cutting‐edge bioengineering innovations, outlining a roadmap for transforming the ...
Zhiyun Liu, Lingyao Zeng, Xulin Gan, Yilin Zhou, Han Shen, Dan Wu, Xin Shou, Minmin Jiang, Liyun Shi   +8 more
wiley   +1 more source

Comparison of the Diagnostic Performance of Multiparametric Prostate Magnetic Resonance Imaging Results with Classical Parameters for Prostate Carcinoma in Gray Zone Patients

Journal of Urological Surgery
Objective: To compare the diagnostic value of prostate imaging-reporting and data system (mpMRI) version 2.0 with classical parameters for prostate cancer detection in gray zone patients with ultrasonography-guided prostate biopsy as a reference point ...
Coşkun Bostancı, Demirhan Örsan Demir
doaj   +1 more source

Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml−1

Asian Journal of Andrology, 2015
Percent free prostatic-specific antigen (%fPSA) has been introduced as a tool to avoid unnecessary biopsies in patients with a serum PSA level of 4.0-10.0 ng ml−1 , however, it remains controversial whether %fPSA is effective in PSA range of 10.1-20.0 ng
Rui Chen, Li-Qun Zhou, Xiao-Bing Cai, Li-Ping Xie, Yi-Ran Huang, Da-Lin He, Xu Gao, Chuan-Liang Xu, Qiang Ding, Qiang Wei, Chang-Jun Yin, Shan-Cheng Ren, Fu-Bo Wang, Ye Tian, Zhong-Quan Sun, Qiang Fu, Lu-Lin Ma, Jun-Hua Zheng, Zhang-Qun Ye, Ding-Wei Ye, Dan-Feng Xu, Jian-Quan Hou, Ke-Xin Xu, Jian-Lin Yuan, Xin Gao, Chun-Xiao Liu, Tie-Jun Pan, Ying-Hao Sun, on behalf of Chinese Prostate Cancer Consortium   +28 more
doaj   +1 more source

[Isoforms of free prostate-specific antigen].

Der Urologe. Ausg. A, 2004
Detection of prostate-specific antigen remains the mainstay in the early detection of prostate cancer. A problem yet unsolved is the lack of specificity of this organ- but not cancer-specific marker, which generates subsequent, invasive procedures in a high number of patients without detecting prostate cancer.
Haese, A, Noldus, J, Steuber, T, Huland, H, Lilja, H   +4 more
openaire   +3 more sources

Molecular and functional analysis of the tumour antigen T21

, 2015
Immunotherapy is a valuable approach to target tumour cells by stimulating the body’s adaptive immune system. To achieve this objective, it is important to identify and study antigens that are distinctively expressed in cancer and can be used effectively
Alshehri, BM
core